OSI Pharmaceuticals (OSIP) - formerly Oncogene Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (316)	11/15/2005 1:00:44 AM
From: Miljenko Zuanic	Read Replies (1) of 447

Thanks, Latest script data confirm my concern that Tarceva will have hard time to penetrate second-line NSCLC segment, unless they generate convincing trials data for monotherapy and/or additive with chemo. At this time I will not bank on Avastin/Tarceva combination. Bottom line, is OSIP concern about current Tarceva limits, so buying Eyetech is to refocus investors toward somewhere else than core business? Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next